Medication – hesit

Rachel Reeves is under pressure to cut free prescriptions for 60 to 65-year-olds

hesiti — Tue, 08 Oct 2024 13:42:22 +0000

Rachel Reeves is facing growing pressure to scrap free prescriptions for 60 to 65-year-olds.

The move could raise more than £6 billion for the Treasury over ten years, according to a previous Government report.

The proposal comes from the charity Intergenerational Foundation, which argues that linking free education to the state pension age of 66 years could help solve the 22 billion deficit in the economy.

The proposal comes as Labor has announced plans to cut the Winter Payments for millions of pensioners, sparking a debate over the party’s approach to older patients.

In England, most patients now pay for their prescriptions. The cost rose to £9.90 per item in April, an increase of 2.6 per cent from 2023. However, some groups are exempt from the charges, including children, pregnant women, and those receiving benefits. .

Apparently, those aged 60 and over also get free prescriptions, a scheme that has been in place since 1995 when it was aligned with the national pension age.

Linking free orders to the state pension age of 66 could help tackle a £22bn deficit in the economy.

Getty

Although the state pension age has been raised to 66, those over 60 still benefit from free prescriptions, creating a divide between the two thresholds.

Liz Emerson, executive director of the Intergenerational Foundation, argued that taxpayers are spending too much money to buy free medicine for those who are still working.

He says: “Linking free orders to the state pension system will improve intergenerational fairness by reducing the cost of the current $1.1 billion in annual distributions, of which part 90 percent of which is free of charge.”

This proposal aims to address the growing disparity between the doctor’s licensure age and the state’s retirement age, which has increased over time.

The charity suggests that this change could help balance the needs of different generations as they deal with financial difficulties. A federal report in 2021 found that raising the limit could raise $6.2billion over 10 years.

However, concerns remain about the potential impact on the low-income 60-65 age group. A 2021 Government review suggested that removing free prescriptions could cost people of this age between £50 and £100 a year for medicines.

The former Conservative government under Rishi Sunak ruled out this policy change in 2023 after extensive consultation.

The Department of Health and Social Care said there were no immediate plans to change the eligibility criteria for the prescriptions.

However, the debate continues as the Government grapples with economic pressures and intergenerational justice. A savings of about $6.2 billion over ten years remains an attractive prospect for policymakers.

Labour’s recent decision to cut Winter Fuel Payments for more than 10 million pensioners is expected to save the Treasury £1.4billion.

Dr Kristian Niemietz, an expert at the Center for Economic Planning, suggested that Labour’s electoral base was biased towards young and middle-aged voters, making the elderly an easy target for savings.

He said: “They won’t want pensioner poverty to rise, but the way to measure old-age benefits is to save money while protecting the poor to reduce costs.”

Dr Niemietz went on to argue against age-based parole, saying: “I would not parole people based on their age. I would parole them because of poverty, or because of to be sick, but not to be born before a certain year.”

Dennis Reed, director of Silver Voices, fears the Prime Minister will not stop there if he is allowed to get away with cutting Winter Fuel Payments.

Chancellor Rachel Reeves will deliver the first Labor Budget on Wednesday 30 OctoberPA

He warned that urgent measures must be taken to protect the 2-3 million adults who will suffer the most with the loss of the loss of the payment of £ 300.

Reed told the Express: “If the Government successfully weathers this storm, they will push older people further, perhaps through free tests, bus transport and even the state pension.

“It’s time for adults to fight for our dignity in our remaining years on this planet.”

As the Budget approaches on 30 October, all eyes will be on the Chancellor’s announcements about possible tax changes and benefits reforms.

The ongoing debate highlights the complex balance between supporting an aging population and managing public finances, a challenge that is likely to continue in the coming years.

#Rachel #Reeves #pressure #cut #free #prescriptions #65yearolds

‘Dirty drugs’ and schizophrenia: After 70 years, there has been a ‘game-changing’ development.

hesiti — Tue, 08 Oct 2024 12:42:04 +0000

Cameron Solnordal says medication for schizophrenia, the complex mental health condition he lives with, can be a burden.

A supporter of mental health organization SANE, Solnordal told SBS news that the side effects of antipsychotic drugs and the weight gain they often cause can be life-threatening and prevent people from taking them.

Solnordal says that when he started taking medication for schizophrenia twenty years ago, he gained 40kg in the first few years.

“When you’re learning about how medications affect you, and if you’re a new patient, you’re going to carry that burden because as well as feeling tired, you’re really tired, you’re eating all the time. and just part of the coping mechanism,” he said.

“It has a huge impact on dating. When people say they don’t want to take it, it’s because they hate the way they feel – that’s the number one reason.”

Recently, a new drug was approved for the treatment of schizophrenia by the United States Food and Drug Administration (FDA). It is the first time in more than 70 years that a new class of medicine has been approved for the treatment of this condition.

Cobenfy (originally called KarXT) is a combination therapy of two different drugs: xanomeline and trospium.

This drug targets a different set of receptors in the brain than existing antipsychotic drugs used to treat schizophrenia.

Although modern drugs work on the brain’s dopamine system, Cobenfy focuses on the cholinergic system, which plays an important role in memory, digestion, heart rate, blood pressure and movement.

Professor Ashley Bush, a researcher at the Florey Institute of Neuroscience and Mental Health in Melbourne, told SBS News she was “very pleased” with the FDA’s decision to approve Cobenfy.

“I think it gives hope. The psychiatric community is cautiously optimistic that this might be a new asset to add to the resources for schizophrenia. I think it gives hope for the patient and the psychiatrist,” he said.

What is schizophrenia?

Schizophrenia is a complex mental health condition that affects around 1% of the population, around 200,000 people in Australia and around 24 million people worldwide.

It is characterized by delusions, hallucinations, disorganized speech and behavior and catatonic behavior (lack of response to the environment or people).

Schizophrenia symptoms are often divided into positive symptoms, which include hallucinations or delusions, and negative symptoms, which include decreased mood and social withdrawal.

What medications are used to treat schizophrenia?

There are currently two types of medications used to treat schizophrenia, including “typical” antipsychotics, which were the first generation of schizophrenia medications developed in the 1950s, and “atypical” ” antipsychotics, which were introduced in the 1990s.

Common antipsychotics include drugs such as Chlorpromazine, which was the first antipsychotic drug to be formulated with compounds used to treat epilepsy and sedation.

Atypical antipsychotics include medications such as Clozapine and Risperidone.

However, the side effects of these drugs can be extensive and debilitating. Antipsychotics have been shown to cause weight gain, type 2 diabetes, elevated cholesterol, life-threatening constipation, and a decrease in white blood cells.

Arthur Christopoulos, lecturer in the department of Pharmacy and Pharmaceutical Sciences at Monash University, told SBS News that existing antipsychotics are “dirty drugs” because they target a large number of receptors and cause many side effects.

“[Cobenfy] he said, “It’s more targeted medicine.”

Where is Cobenfy from?

Christopoulos said the journey to get Cobenfy approved began nearly three decades ago after pharmaceutical researchers discovered molecules that could selectively target receptors known as important to control the neurological effects associated with Alzheimer’s disease and schizophrenia.

The drug xanomeline was tested on Alzheimer’s patients but the trials failed due to serious side effects. However, they showed that the drug significantly reduced the symptoms of psychosis.

Later, xanomeline was combined with trospium to reduce unwanted side effects and this combination became the drug that is now approved as Cobenfy.

Christopoulos and other Monash University researchers were involved in a global study to develop this drug.

Christopoulos said Cobenfy could be considered an “add-on” to current antipsychotic drugs and could be used alongside them.

“Targeting this receptor system, it’s a game changer,” he said.

Although the trials that led to its approval in the US were only five weeks long, the FDA said that patients who received Cobenfy “experienced a significant reduction in symptoms” compared to the placebo group.

Providing information for the drug warns that it can cause urinary retention, increased heart rate, and decreased bowel movement, and is not recommended for patients with liver failure.

Christopoulos said that while it may not be a “panacea” it offers a completely different option for medicine.

“It will have a huge impact on the lives of people with schizophrenia in Australia and internationally,” he said.

“If I had to choose, I would rather take this drug than the existing antipsychotics.”

Christopoulos said it was too early to say whether the drug would help treat what is known as ‘schizophrenia-resistant schizophrenia’, where people continue to have symptoms despite taking antipsychotic drugs.

Treatment-resistant schizophrenia affects about a third of people diagnosed with the disease.

When will it be available in Australia?

Christopoulos said it was unclear when Cobenfy would be approved by Australia’s Therapeutic Goods Administration (TGA) but said “it will happen”.

He said there were fast-tracks to TGA approval but it was uncertain whether they would be used.

A spokesperson for the TGA told SBS News that it had not yet received an application to register Cobenfy on the Australian Register of Therapeutic Goods.

“The TGA is aware that the United States Food and Drug Administration has approved Cobenfy. If the TGA approves the application, it is important to note that the TGA will review all the information independently and make its decision based on the Australian standards,” they said. .

Christopoulos also said that, without the Pharmaceutical Benefits Scheme, the drug could be too expensive for some people.

As for Australians living with schizophrenia, Solnordal said many people could be relieved by the arrival of a new medication option.

“If someone sat down and said ‘Let’s try to do something better with schizophrenia and treatment’ then of course people will hang their heads and say ‘finally!’

“It’s such a do-it-yourself approach with what we’ve got … we’re just managing day-to-day.”

#Dirty #drugs #schizophrenia #years #gamechanging #development

FDA Approves Use of Up to Three Tubes of Ameluz (aminolevulinic acid HCI) by Biofrontera Inc., 10% in One Treatment.

hesiti — Mon, 07 Oct 2024 12:45:00 +0000

Biofrontera Inc. Share Description

The approval allows a larger field treatment of actinic keratosis (AK) on the face and skin with Ameluz.^®-PDT uses BF-RhodoLED or RhodoLED XL lamp
Supplemental New Drug Application (sNDA) supported by two Phase 1 safety studies
AK is the second most common test performed by dermatologists in the United States¹
An estimated 13 million treatments are provided annually for AK in the US²

WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”)a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the US Food and Drug Administration (FDA) has approved the Company’s sNDA to increase the approved dosage from one to three tubes of Ameluz.^® with treatment.

This approval allows health professionals to have more flexibility to handle large or multiple treatment areas for patients undergoing photodynamic therapy (PDT) for AK on the face and scalp, which which leads to greater convenience for health care providers and their patients.

“We are pleased with the FDA’s decision to approve the use of up to three tubes of Ameluz.^® per treatment,” said Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc. “We are currently working with Medicare and commercial payers to obtain reimbursement for the label update and will notify consumers rightfully ours.”

The sNDA was supported by two Phase I safety studies in which three tubes of Ameluz^® were used in 116 patients. Studies have shown that the blood pressure of the active ingredient and metabolites were several orders of magnitude lower than those known to have side effects, and that the adverse events of the administration area and application were similar to those seen with a single tube of Ameluz.^®.

“Ameluz.”^® is the only PDT photosensitizer indicated by the FDA for the treatment of wound-driven and field-directed AKs. This approval will allow dermatologists to provide the full range of options they desire for their patients, while maintaining the proven efficacy and safety of Ameluz.^®. It is another important event for Biofrontera as we continue to demonstrate our commitment to PDT and our dedication to the development of this important treatment method,” explains Dr. Luebbert.

“Up to 60% of squamous cell carcinomas begin as AK lesions that cannot be treated, so it is important to be able to treat the entire affected area. I used Ameluz^® now for more than 7 years for the AK system because of the proven effectiveness and safety it provides. With the approval of the sNDA, I expect to be able to use about three tubes for patients who need them,” said Dr. Jonathan Weiss, researcher and co-managing partner of Georgia Dermatology Partners, Atlanta.

About Actinic Keratosis

AK is a very common precancerous skin lesion caused by chronic sun exposure, which if left untreated, can develop into a life-threatening skin cancer called squamous cell carcinoma. AKs usually appear on sun-exposed areas such as the face, scalp, arms or back of the hands. In 2020, approximately 58 million people in the US were affected by AK and 13 million AK treatments were performed.³

Landis ET. and al. Dermatol Online J. 2014 Apr 16;20(4):22368.
Market data is available from CMS and IQVIA, 2021
www.skincancer.org/skin-cancer-information/actinic-keratosis/

Biofrontera Inc. Share Description

Biofrontera Inc. is a US-based biopharmaceutical company specializing in PDT-targeted skin conditions. The company sells a combination of the drug Ameluz® and RhodoLED^® light series for PDT of AK, precancerous skin lesions that may progress to invasive skin cancer. The company is conducting clinical trials to expand the product’s use in treating non-melanoma skin cancer and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera’s business prospects and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and assumptions about future events. However, actual results or events may differ materially from the plans, intentions and expectations expressed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the effect of any unusual external events; any changes in the Company’s relationships with licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; The Company’s ability to achieve and maintain profitability; whether current global supply chain disruptions will affect the Company’s ability to acquire and distribute its licensed products; changes in health care provider practices, including any changes in performance, reimbursement and pricing of procedures using the Company’s licensed products; uncertainties in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; either the results of the first clinical trials or the Ameluz trials ^® in conjunction with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties related to regulatory review of clinical trials and marketing authorization applications; whether the market potential of Ameluz together with BF-RhodoLED and/or RhodoLED XL is consistent with the Company’s expectations; the Company’s ability to retain and hire key personnel; adequacy of financial resources and the need for additional funds; and other information that may be disclosed in the Company’s filings with the Securities and Exchange Commission (“SEC”), which can be found on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, estimates, expectations and beliefs. The Company does not intend to update any such forward-looking statements and expressly disclaims any obligation to update the information contained in this press release except as required by law.

Contact:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com

#FDA #Approves #Tubes #Ameluz #aminolevulinic #acid #HCI #Biofrontera #Treatment

Here’s how much you’ll pay for Ozempic across Ireland

hesiti — Sun, 06 Oct 2024 08:55:31 +0000

One thing Santa won’t be bringing this year is a new supply of the type 2 diabetes drug, Ozempic. A ‘wonder drug’ that is popular for being an appetite suppressant, it is more known for its weight loss benefits than anything else.

Many people suffering from type 2 diabetes are still complaining about the price of the drug and what’s worse, the lack of stability in different pharmacies. The HSE says they do not set the Olympic price, which is between the pharmacy and the supplier.

EVOKE researched the cost of Ozempic across the country to find out which counties charge the most and which counties charge the least for the sought-after drug.

Ozempic. Michael Siluk/UCG/Universal Images Group via Getty Images

Perhaps surprisingly, Dublin did not seem to pay much for a weekly injection. Everywhere, Ozempic appears to be priced at €133-€155, with a few retailers charging as much as €185 for the drug.

On top of this, it is very difficult to find this drug. Almost all the pharmacies that shared their prices also added that they have no product left, due to the high number of people desperate to get their hands on it.

A pharmacist told EVOKE that the drug’s distributor has sent a letter to distributors nationwide to say that Ozempic will no longer be available this fall or winter. Any chemists selling the drug this fall will have it in stock. Here is the price being charged for Ozempic nationwide…

Ozempic. Michael Siluk/UCG/Universal Images Group via Getty Images

Dublin

Northside:

If you’re hoping to find Ozempic in north Dublin, you’re in luck. A pharmacist at Edward McManus Pharmacy in Ballymun explained: ‘It’s very hard to find and we only get patients with medical cards’. The business charges €150 for a month’s supply of the drug.

McCabes Pharmacy in Artane also sells from low prices, which usually come in at €142.

southside:

In south Dublin, the cost of getting a monthly supply of Ozempic is very similar. Meaghers Pharmacy on Baggot Street costs €159 for one month.

At Lloyds in Donnybrook, the drug costs €154 for a one-month supply. Hotels are cheaper than its competitors, apparently charging €133.69 across the board.

Kildare

In Kildare there is also an acute shortage of medicine. McCabes Pharmacy in Athy charges €140 to buy the drug on the spot, €2 cheaper than its counterpart in Dublin.

Meanwhile, at Connolly’s Pharmacy in Kildare Town, it costs €150 to buy a month’s supply.

Laois

If you’ve thought about heading to the Midlands to get Ozempic on the cheap, go back to the drawing board! You will not find that the cost of drugs has dropped significantly.

At Lloyds Pharmacy in Portlaoise, you will pay €140, which is €14 cheaper than its counterpart in Dublin 4. However, if you find yourself in Abbeyleix, you may pay €155 to get hands to Ozempic.

Limerick

Medicine seems to be a little cheaper in Munster, and Limerick seems to be a cheaper city to buy supplies. Lloyds Pharmacy in this area charges €130 for a month’s worth, €24 less than their store in Donnybrook.

O’Malleys Pharmacy charges €134.95, explaining that the price that each pharmacy puts: ‘It depends on their plan and delivery. It is a choice we have made because it is very expensive and is not covered by any plans.’

Kerry

You can expect to pay more when hunting in Ozempic Kerry.

O’Sullivan’s Pharmacy in Killarney charges €185 for a month’s supply, explaining: ‘It depends on demand and the price you pay – where you get it.’

Galway

In Galway, prices are well in line with its competitors as Whelan’s Pharmacy charges €140 and Boots comes in at €133.69.

Mayo

If you’re heading west to find Ozempic, O’Donnell’s TotalHealth Pharmacy in Mayo charges €150 for a month’s supply while Treacy’s Pharmacy sells the drug for €140.

It has disappeared

You’ll be hard-pressed to find an Ozempic for less than €150 in Offaly. One pharmacist explained that they ‘can’t understand how a chemist can charge €130’ for a month’s supply of medicine. They say it may be the case that this drug acts as a loss leader so that when a customer comes in, they also buy something else.

Stratus Healthcare Pharmacy charges €155, while Haven Pharmacy sells the drug for €150.

It should be noted that patients using Ozempic to treat type 2 diabetes can be reimbursed by the HSE under the Long Term Illness Scheme. However, those who use this medicine to treat any other diseases are not entitled to reimbursement.

#Heres #youll #pay #Ozempic #Ireland

Banned 13 years ago, Nimesulide is still prescribed to children; Government Joins Sensitization Drive – News18

hesiti — Sat, 05 Oct 2024 03:43:57 +0000

Despite a 13-year ban on the use of the pain reliever and antipyretic drug Nimesulide in children, reports of side effects continue to reach the drug watchdog – indicating that the drug is still being prescribed , News18 has learned.

Following these results, the watchdog Indian Pharmacopeia Commission (IPC) has urged drug manufacturers to ‘warn’ pediatricians and other healthcare professionals about the importance of not giving this drug to children.

Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) and is approved for sale for adults in India. It helps relieve pain associated with various disease states and reduce high fever that is not controlled by general medicine.

In 2011, the Union Ministry of Health and Family Welfare banned the use of Nimesulide in children under 12 years of age.

In many countries, products containing Nimesulide are not approved for children under the age of 12. This drug is considered hepatotoxic and children are considered at risk of developing liver disease, “Union Department of Health said in a statement dated March 11, 2011.

However, despite the ban, the Pharmacovigilance Program of India (PvPI) – which monitors and collects information on adverse drug reactions (ADRs) and adverse events related to pharmaceutical products – receives complaints.

According to the letter, obtained by News18, the Indian Pharmacopeia Commission (IPC) – which runs the Pharmacovigilance Program of India (PvPI) – has decided to launch an “action” on health professionals and consumers to do not use the drug Nimesulide in children under 12 years of age.

The IPC has written a letter to all drug manufacturers who have marketing authorization for the drug to initiate the process.

Publish information and post notices

While reminding that the Ministry of Public Health in January 2011 prohibited the manufacture, sale and distribution of the drug, the letter dated October 1 said, “PvPI is receiving reports that Nimesulide has caused adverse drug reactions from marketing authorization holders under PvPI.”

It also called for action in the interest of “pediatric patient safety” and urged all health professionals and concerned consumers not to prescribe or administer Nimesulide to minors. 12.

The letter placed the responsibility for the publication of this warning on marketing authorization holders or pharma companies where they are required to “tell this information and warning poster” to “pediatricians, consultants in their hospital and a professional center for spreading awareness…”

What does the new poster say?

A new poster prepared by PvPI to raise awareness, seen by News18, states that “Nimesulide is a painkiller” and is “prohibited for use in children under 12 years of age.”

Showing a child refusing to take the medicine, the poster reads that the drug can cause “liver toxicity, adverse skin effects such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis.”

An old practice, doctors who don’t know can still prescribe: Specialists

Dr. Dinesh Raj, a pediatrician at Delhi’s Holy Family Hospital, was surprised to see Nimesulide used so far.

“Nimesulide is banned in children but, surprisingly, it is still being used. Doctors may not know about the negative effects of Nimesulide in children,” he said while explaining that this medicine is used for fever and pain.

“Besides the common side effects of gastritis, vomiting, abdominal pain etc., it has been associated with serious side effects such as stomach bleeding and liver failure,” he added. by saying.

Dr GV Basavaraja, president of the Indian Academy of Pediatrics (IAP), told News18 that such a mistake can only be made by those who are old doctors and are not updated with the current guidelines.

Also, he said that in remote health care areas such as community health centers (PHCs) or community health centers (CHCs), many pediatricians are not available and are doctors who general or other counselors who give drugs to children. “In this situation, there is a great opportunity to prescribe Nimesulide as doctors (who treat adult patients) may not be aware of the contraindication in children.”

Basavaraja, who is also a renowned pediatrician based in Bengaluru, said that in the last 15 years, he has not written a single prescription for Nimesulide. “The IAP strongly recommends that doctors should not prescribe this drug to children and we will send advice to our 50,000 members again as a reminder.”

Echoing similar sentiments, Dr Maninder Dhaliwal, a pediatric pulmonologist at NCR-based Amrita Hospital, believes that not all doctors may be fully aware of the updated guidelines or may misinterpret the restrictions.

“In some cases, the changes in management are not as well communicated, perhaps in small or rural settings. I don’t think there is a pediatrician who prescribes nimesulide for fever. The prevention is clear but some doctors may prescribe it due to lack of awareness, since in adults it is being used,” Dr. Dhaliwal said.

He also said that “habit and familiarity with the drug in adult medicine can lead to a better understanding of nimesulide. Or sometimes the habits may continue even after regulatory changes, and if only it would be rare.”

#Banned #years #Nimesulide #prescribed #children #Government #Joins #Sensitization #Drive #News18

Ozempic for everyone, Zepbound is back, and the top CEO pays: Pharma news roundup

hesiti — Fri, 04 Oct 2024 09:00:00 +0000

The mayor of Rio de Janeiro promises to make an Ozempic-style version of the city’s health network available – if he wins re-election. The top 5 highest paid CEOs made more than $60 million last year. And CVS Health Corporation (CVS) plans to cut 2,900 jobs as part of a multi-year cost-savings plan aimed at cutting costs and increasing investment in AI.

Check out the stories and medical news highlights from this week.

The mayor promises Ozempic for everyone saying ‘there will be no more fat people’ in his town

In this photo, boxes of the diabetes drug Ozempic sit on a pharmacy counter. – Image: Mario Tama / Staff (Getty Images)

A Brazilian politician runs an interesting campaign: Ozempic for all. Eduardo Paes, the mayor of Rio de Janeiro, is running for re-election and has recently promised to make the generic version of Ozempic available through the city’s public health network if he wins.

Zepbound is no longer lacking. That would hurt weight loss drug sellers

Eli Lilly and the Company’s World Headquarters. – Image: image of jetcity (Getty Images)

The shortage of Eli Lilly’s ( LLY ) diabetes and weight loss drug has officially ended, according to the Food and Drug Administration (FDA). The news could put pressure on companies that have been able to sell GLP-1 weight-loss products because of widespread shortages.

Eli Lilly, Moderna and more: The 5 highest-paid healthcare CEOs

A Moderna logo is seen at the Moderna campus in Norwood, Massachusetts on December 2, 2020, where the biotechnology company is mass-producing its COVID-19 vaccine. – Photo: Joseph Prezioso (Getty Images)

Health care stocks underperformed the broader market in 2023, with many companies missing their profit targets and some CEOs missing out on bonuses. However, despite these obstacles, the executives of the top 300 industrial companies still received an astonishing $3.5 billion in total last year, according to a new report by STAT News. Although the average CEO salary has dropped from $13 million in 2022 to $11 million in 2023, the highest earners still take home more than $100 million each. Here’s how much the top 5 highest paid CEOs in healthcare made in 2023.

The success of weight-loss drugs, gene therapies, and more: 8 clinical trials to watch now

Photo: Kinga Krzeminska (Getty Images)

We’re only a few months away from the end of the year, but pharma companies still have a steady stream of clinical trial results to announce before then. Several companies – including Novo Nordisk (NVO), Viking Therapeutics (VKTX), and Amgen (AMGN) – are expected to post the results of their next weight loss drugs. Also, CRISPR Therapeutics (CRSP) intends to share preliminary findings from the experimental trial CTX112, a genetically engineered cell therapy for cancer and autoimmune diseases. Learn more about these tests and others to watch.

Drugs like Ozempic are now more popular than insulin for treating diabetes

Ozempic is a drug for adults with Type 2 diabetes that, along with diet and exercise, can improve blood sugar — although some doctors prescribe it “off-label” for lowering body weight. – Image: Steve Christo – Corbis / Contributor (Getty Images)

GLP-1 drugs like Ozempic took just seven years to overtake insulin as the second most common treatment for Type 2 diabetes, according to a new report by a market research firm and Trilliant Health review.

CVS will cut up to 3,000 jobs as it plans AI investments — and considers a spin-off.

A general view of the CVS Pharmacy store in Aug. 23, 2024, Oceanside, New York. – Photo: Bruce Bennett / Staff (Getty Images)

CVS Health Corporation (CVS) plans to cut about 2,900 jobs as part of a $2 billion cost-savings plan aimed at cutting costs and increasing investments in technology.

New weight loss drugs could be developed very quickly if Roche gets its way

The logo on the exterior of the Silicon Valley headquarters of pharmaceutical company Roche in Santa Clara, California. – Image: Smith Collection/Gado/Donor (Getty Images)

Roche ( RHHBY ) told investors on Monday that it plans to cut the cost and time it takes to develop new drugs, including an experimental weight loss and diabetes drug.

Costco, Hims, Noom, and more: 6 companies that started selling weight loss products this year

Image: Images: Reuters Photo, Hollie Adams, Hims & Hers, NurPhoto / Contributor

The explosion in sales of weight loss drugs has made Novo Nordisk (NVO) and Eli Lilly (LLY) the world’s most valuable pharmaceutical companies. This constant demand has not only led to an ongoing deficit but has also boosted Denmark’s GDP over the past year. Analysts at Morgan Stanley (MS) predict that the global market for GLP-1 drugs could reach $105 billion by 2030. With so much money, many companies have begun to offer weight loss medication.

Check out which companies have entered the weight loss market this year.

For the latest news, Facebook, Twitter and Instagram.

#Ozempic #Zepbound #top #CEO #pays #Pharma #news #roundup